ArticleRSC advances2025
Trials of a drug release platform in near-spherical porous NiTi alloys containing a thermosensitive hydrogel as the inner coating.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Functional Vascular Stents for Cardiovascular Therapy with Drug Delivery and Computational Design.Pharmaceutics · 2026Review
- Biomedical titanium-tantalum alloys for orthopedic implant applications: From manufacturing to biological performance.Bioactive materials · 2026Review
- Shape memory hydrogels in tissue engineering: Recent advances and challenges.Bioactive materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a preliminary investigation of porous nickel-titanium (NiTi) materials with controllable porosity fabricated through metal injection molding combined with the powder space-holder method (MIM-PSH). The thermosensitive hydrogel Pluronic F-127 was utilized as a drug carrier to load the anti-proliferative drug rapamycin, resulting in porous NiTi-hydrogel composite materials for controlled drug release. By tuning the NiTi matrix porosity (0%, 20%, and 40%), the system achieved precise modulation of drug loading capacity and release kinetics. Notably, the 40% porous NiTi composite exhibited a threefold increase in the drug-loading capacity and sustained release over 17 days. This hybrid design leveraged the thermoresponsive properties of the hydrogel and the tailored pore architecture to enable spatiotemporal control of rapamycin delivery, effectively inhibiting human aortic smooth muscle cell proliferation and mitigating
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.